Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03739827|
Recruitment Status : Recruiting
First Posted : November 14, 2018
Last Update Posted : February 8, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order to learn more about how these tumors develop. The information obtained from this study may lead to improved screening, preventive guidelines, and treatments.
To better understand rare cancers and hereditary cancer syndromes.
People who have a rare tumor, a family history of a rare tumor, a hereditary cancer syndrome, or a mutation that leads to rare tumors.
Participants will be screened with questions about their medical history and/or that of their family members. They will give a saliva sample.
Participants who have a tumor will have their medical records and tests reviewed. They will answer questions about their wellbeing and needs. They may provide a tumor tissue sample.
Participants may also have:
- Physical exam
- Clinical photography
- Blood, urine, saliva, and stool samples taken
- Consultation with specialists
- A scan that produces a picture of the body. Either one that uses a small amount of radiation, or one that uses a magnetic field.
- Genetic testing/genetic counseling.
Participants will be contacted once a year. They will answer updated questions about their medical and family history.
Participants will be asked to contact the study team if there are changes in their tumors.
Participants may be invited to join focus groups for people with the same diagnosis of rare tumors.
Participants may be invited to participate in other NIH protocols.
RARE TUMOR LIST:
- Acinar cell carcinoma of the pancreas
- Adenosqaumous carcinoma of the pancreas
- Adrenocortical carcinoma
- Alveolar soft part sarcoma
- Anaplastic Thyroid Cancer
- Atypical Teratoid Rhabdoid Tumor/MRT
- Carcinoma of Unknown Primary
- Chondromyxoid fibroma
- Clear cell renal carcinoma
- Clear Cell Sarcoma
- Clear cell sarcoma of kidney
- Conventional chordoma
- Dedifferentiated chordoma
- Desmoplastic small round cell tumor
- Epithelioid hemangioendothelioma
- Ewing Sarcoma
- Fibrolamellar carcinoma
- Fusion negative rhabdomyosarcoma
- Fusion positive renal cell carcinoma
- Fusion positive rhabdomyosarcoma
- Gastro-enteropancreatic neuroendocrine tumor
- Hereditary Diffuse Gastric Cancer
- Inflammatory myofibroblastic tumor
- Kaposiform hemangioendothelioma
- Malignant ectomesenchymal tumor
- Malignant peripheral nerve sheath tumor
- Malignant triton tumor
- Medullary thyroid cancer
- Mixed acinar adenocarcinoma
- Mixed acinar neuroendocrine carcinoma
- Myxoid Liposarcoma
- Neuroendocrine tumors
- NUT midline carcinoma
- Pancreas ductal adenocarcinoma with squamous features
- Pancreatic acinar cell carcinoma
- Papillary renal cell carcinoma
- Parosteal Osteosarcoma
- Periosteal Osteosarcoma
- Peripheral nerve sheath tumor
- Peripheral primitive neuroectodermal tumor
- Pituitary cancer
- Poorly differentiated chordoma
- Renal medullary carcinoma
- Round cell Liposarcoma
- Sclerosing Epithelioid Fibrosarcoma
- SDH deficient GIST
- SMARCB1 deficient tumors
- SMARCA4 deficient tumors
- Synovial sarcoma
|Condition or disease|
|Malignant Solid Tumors Other Neoplasms Solid Tumors Pediatric Solid Tumor Refractory Solid Tumors Solid Tumor|
|Study Type :||Observational|
|Estimated Enrollment :||10000 participants|
|Official Title:||Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors|
|Actual Study Start Date :||January 28, 2019|
|Estimated Primary Completion Date :||May 31, 2023|
|Estimated Study Completion Date :||March 31, 2028|
Subjects with a diagnosis of rare tumor (fewer than 15 cases in 100,000 people per year)
Relatives of subjects with a rare tumor who have a germline genetic variant that predispose to a rare solid tumor or a subject who has a germline genetic variant that predispose to a rare solid tumor
Relatives of subjects with a diagnosis of rare tumor that do NOT have known germline genetic variants that predispose to a rare solid tumor.
4/ Cohort 4
Parents/guardians of children with a diagnosis of rare tumor participating in focus groups (if not enrolled in Cohorts 1, 2 or 3)
- To comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival) [ Time Frame: 10 years ]To comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||4 Weeks and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
- INCLUSION CRITERIA:
- Cohort 1: Participants with a diagnosis of a rare solid tumor (fewer than 15 cases in 100,000 people per year). There are no age restrictions beyond the neonatal period (4 weeks).
-Cohort 2: Participants without a rare tumor who have a germline genetic variant that predisposes to a rare solid tumor
-Cohort 3: Relatives of participants with diagnosis of rare solid tumors who do NOT have a known germline variant that predisposes to a rare solid tumor
- Cohort 4: Parent/guardian of child participating in a focus group if not already enrolled on the study.
- Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03739827
|Contact: Barbara (BJ) Thomas, R.N.||(240) email@example.com|
|Contact: Mary F Wedekind Malone, D.O.||(240) firstname.lastname@example.org|
|United States, District of Columbia|
|Children's National Medical Center||Recruiting|
|Washington, District of Columbia, United States, 20010|
|Contact: AeRang Kim 301-451-7025 email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|United States, Oregon|
|Oregon Health and Science University||Recruiting|
|Portland, Oregon, United States, 97239|
|Contact: Takumi Suzuki 503-494-3621 firstname.lastname@example.org|
|United States, Texas|
|Texas Children's Hospital||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Gaylon Stevenson (713) 798-495_ email@example.com|
|Principal Investigator:||Mary F Wedekind Malone, D.O.||National Cancer Institute (NCI)|
|Responsible Party:||National Cancer Institute (NCI)|
|Other Study ID Numbers:||
|First Posted:||November 14, 2018 Key Record Dates|
|Last Update Posted:||February 8, 2023|
|Last Verified:||January 24, 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||.All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
|Time Frame:||Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.|
|Access Criteria:||Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Service to the Patients
Knowledge about the Nature of Cancer